Minerva Neurosciences swings to Q3 net income of $100.7 million
NERV•Minerva Neurosciences reported third-quarter 2026 GAAP net income of $100.7 million, versus a loss a year earlier, driven by a $109.6 million non-cash gain from changes in the fair value of its warrant liability.
1. Quarterly results
Minerva Neurosciences swung to third-quarter 2026 GAAP net income of $100.7 million from a year-earlier loss. A $109.6 million non-cash gain from changes in the warrant liability’s fair value drove the profit. Research and development expenses rose to $5.2 million, and general and administrative expenses increased to $4.3 million year over year.
2. Trial timeline
The ongoing confirmatory Phase 3 roluperidone trial remains on track for topline efficacy data in the second half of 2027.
